Trinity Biotech is a commercial-stage biotechnology company specializing in the development, manufacturing, and marketing of clinical diagnostic products for both clinical laboratories and point-of-care settings. The company focuses on human diagnostics and diabetes management solutions, including wearable biosensors. Its product range is designed to detect various health conditions, such as autoimmune diseases, infectious diseases, sexually transmitted infections, diabetes, and disorders affecting the liver and intestine. Additionally, Trinity Biotech supplies raw materials to the life sciences and research sectors worldwide. The company's products are marketed under several brand names, including Recombigen, Unigold, MarBlot, Mardx, and Immublot. Geographically, Trinity Biotech operates primarily in two segments: the Americas and the Rest of World, with the majority of its revenue derived from the Americas.
Novus Diagnostics is focused on developing an innovative diagnostic device aimed at detecting sepsis. This technology allows for the rapid and automated identification of pathogens present in whole blood samples. By providing results in minutes, Novus Diagnostics empowers healthcare providers to initiate effective treatment for sepsis patients quickly and efficiently. The approach not only enhances patient care but also aims to reduce costs associated with sepsis management.
EpiCapture
Acquisition in 2024
EpiCapture is a company focused on enhancing cancer patient care through the development of non-invasive urine tests designed for the early detection and monitoring of aggressive cancers. The company specializes in liquid biopsy tests that utilize urine DNA to assess epigenetic biomarkers associated with aggressive prostate disease. By generating a score that indicates the likelihood of aggressive cancer, EpiCapture's tests enable healthcare professionals to identify prostate cancer at an early stage, potentially reducing the necessity for more invasive treatments. Through its innovative approach, EpiCapture aims to improve prognostic assessment and patient outcomes in oncology.
Novus Diagnostics
Corporate Round in 2024
Novus Diagnostics is focused on developing an innovative diagnostic device aimed at detecting sepsis. This technology allows for the rapid and automated identification of pathogens present in whole blood samples. By providing results in minutes, Novus Diagnostics empowers healthcare providers to initiate effective treatment for sepsis patients quickly and efficiently. The approach not only enhances patient care but also aims to reduce costs associated with sepsis management.
Metabolomic Diagnostics
Acquisition in 2024
Metabolomic Diagnostics Ltd. is a medical diagnostics company based in Little Island, Ireland, founded in 2011. The company specializes in developing advanced diagnostic solutions that utilize mass spectrometry technology for biomarker analysis. Its primary focus is on providing predictive diagnosis for pre-eclampsia, a serious condition characterized by high blood pressure and proteinuria during pregnancy. Metabolomic Diagnostics has created a pipeline for identifying diagnostic biomarker panels, which are then translated into clinical assays for laboratory use. This innovative platform allows for the simultaneous detection and quantification of multiple biomarkers, facilitating meaningful insights for disease diagnosis and risk prediction.
imaware
Convertible Note in 2023
imaware is a health technology company focused on enhancing individual well-being through accessible testing solutions. The company provides scientifically validated home-based tests that enable users to screen and monitor a variety of health conditions, including diabetes, prostate cancer, thyroid issues, and autoimmune diseases. By leveraging a patient-facing platform, imaware facilitates a digitally-native care model that encompasses logistics, laboratory analysis, telehealth support, and compliance expertise. This approach aims to deliver a seamless user experience, allowing patients, providers, employers, and brands to access reliable and convenient healthcare solutions from the comfort of their homes.
IMMCO Diagnostics
Acquisition in 2013
IMMCO Diagnostics specializes in the development and provision of diagnostic products and services, primarily focused on autoimmune diseases. The company offers a range of innovative medical devices and assays that address various conditions, including collagen vascular disorders, gastrointestinal and liver diseases, vesiculo-bullous disorders, endocrine issues, neuroimmunological conditions, cardiovascular disorders, and hearing loss. In addition to its diagnostic devices, IMMCO Diagnostics provides a comprehensive array of laboratory testing services, encompassing serology, genetics, and pathology across multiple medical specialties, such as dermatology, endocrinology, gastroenterology, ocular pathology, oral pathology, otolaryngology, neurology, and rheumatology. The integration of cutting-edge research and diagnostic expertise positions IMMCO Diagnostics as a leader in autoimmune disease diagnostics.
Fiomi Diagnostics
Acquisition in 2012
Fiomi Diagnostics specializes in the development and marketing of diagnostic test kits, focusing on a panel of point-of-care cardiac marker assays. The company employs advanced technology that achieves picomolar sensitivity for whole-blood in vitro diagnostic immunoassays at the point of care. This innovative approach utilizes a microstructured plastic chip that ensures a consistent flow of fluid in lateral flow assays, coupled with an efficient fluorescence detection system that delivers quantitative test results.
Phoenix Biotech
Acquisition in 2011
Phoenix Bio-Tech Corp is a developer and manufacturer of medical diagnostic products, specializing in the automation of diagnostic systems. The company offers a range of recombinant-based ELISA products focused on infectious diseases, including the TREP-SURE EIA, which is used for the qualitative detection of treponema pallidum antibodies in human serum or plasma. Additionally, it provides the TREP-CHEK Test Kit, a confirmatory enzyme immunoassay for the qualitative detection of treponema pallidum IgG antibodies. Phoenix Bio-Tech is committed to providing technical services alongside its diagnostic offerings to enhance the effectiveness of medical testing.
Primus Corp
Acquisition in 2005
Primus Corp is designs, manufactures, and supplies hemoglobin variant testing, thalassemias, and newborn screening systems. It offers direct injection and automated analyzers; and dual-assay analyzers for the measurement of HbA1c, as well as in the identification and quantization of A2, F, and Hb variants. The company provides PDQ, a semi-automated equipment for the physician's office, clinics, and medium-size hospital laboratories; PDQ Plus, an automated equipment and method for clinics, medium-size and large hospitals, and reference labs; and Primus ultra2 resolution, a system for the detection of hemoglobinopathies using whole blood, manual hemolysates, or blood spot samples on filter paper.
Fitzgerald Industries International
Acquisition in 2004
Fitzgerald Industries International is a manufacturer and supplier of biological reagents based in Acton, Massachusetts. The company specializes in producing primary and secondary antibodies, recombinant and native proteins, ELISA kits, and serum and plasma. Fitzgerald Industries places a strong emphasis on customer service, striving to meet the unique needs of researchers by offering personalized technical support and customized products. The core team consists of scientists who understand the challenges faced in laboratory settings, allowing them to provide empathetic and effective assistance to their clients. Through a commitment to high-quality products and competitive pricing, Fitzgerald Industries aims to support the scientific community in advancing their research efforts.
MarDx Diagnostics
Acquisition in 2000
MarDx Diagnostics is engages in developing, manufacturing, and marketing diagnostic products in the United States. It offers Western Blot, which is used to test and confirm the primary diagnosis of certain infectious diseases, including lyme disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.